SLC6A15

Across TCGA pan-cancer cohorts, SLC6A15 Mutation is linked to patient survival in 8 of 34 cancer types, making it a survival-associated SLC6A15 data layer compared with 27 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in small cell lung cancer (SCLC), where higher SLC6A15 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated SLC6A15 expression acts as an unfavorable survival marker, although some lineages such as STAD and UCEC show a favorable association.

SCLC, PAAD, and STAD are the cancer types where SLC6A15 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SCLC	OS	Median	II,III,IV	0.082	0.702	<.001	36	view →
PAAD	OS	Median	All	0.060	0.641	<.001	12	view →
STAD	DFS	Median	All	1.000	0.390	.030	12	view →
LIHC	OS	Median	III,IV	0.123	0.655	<.001	12	view →
SKCM	DFS	Median	All	0.063	0.757	<.001	9	view →
READ	OS	Median	IV	0.289	0.899	<.001	6	view →
LUSC	OS	Median	III,IV	0.178	0.683	.040	6	view →
UCEC	DFS	Median	II,III,IV	0.906	0.440	.042	2	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

SLC6A15–SCLC (OS)

Open the SCLC breakdown →